- At the end of Cycle 8 (i.e. completion of Belinostat), subjects who achieve or maintain a complete molecular response (CMR) with no evidence of minimal residual disease (MRD) will continue to receive AZT (±IFN-alfa). Subjects with MRD with no clinical evidence of disease progression nor clinical evidence of ATLL may also continue to receive AZT (± IFN-alfa) OR be removed from treatment at the discretion of the Investigator.